Halaven (Eribulin)

Halaven is a prescription injectable solution that contains the active ingredient eribulin. It is supplied in a standard strength (specific milligram amount varies by market) and is administered intravenously. Classified as a microtubule inhibitor and antineoplastic agent, Halaven is used in the European Union for the treatment of certain advanced cancers. Its mechanism involves inhibition of microtubule growth, leading to cell‑cycle arrest and apoptosis in patients.

Halaven (eribulin) is indicated for intravenous treatment of adult patients with specific malignant tumors that have progressed after prior chemotherapy. The drug is approved in the European Union for use in two main cancer types, reflecting its activity against rapidly dividing cells.

- Metastatic breast cancer that has received at least two prior chemotherapeutic regimens - Advanced (unresectable or metastatic) liposarcoma after prior anthracycline‑containing therapy - Patients with disease progression despite standard therapies - Use as part of a multidisciplinary oncology treatment plan

Side effects of Halaven vary in frequency and severity. They are reported by patients receiving the intravenous formulation.

Common: - Fatigue - Neutropenia - Anemia - Nausea - Alopecia - Peripheral neuropathy - Constipation

Serious: - Febrile neutropenia - Severe infection - Pulmonary toxicity - Cardiac dysfunction - Tumor lysis syndrome - Severe allergic reactions

Before initiating Halaven, clinicians should evaluate patient history and monitor for potential risks associated with antineoplastic therapy.

- Assess baseline blood counts and organ function - Monitor for signs of infection or febrile neutropenia - Evaluate cardiac status in patients with pre‑existing heart disease - Use caution in patients with hepatic impairment - Counsel patients on the risk of peripheral neuropathy and provide supportive care measures - Discuss contraception and pregnancy considerations, as safety data are limited

Halaven may interact with other medications that affect bone marrow function or hepatic metabolism. Awareness of these interactions helps reduce adverse outcomes.

Avoid: - Concurrent use of other myelosuppressive chemotherapy agents - Strong CYP3A4 inducers that could reduce eribulin exposure - Live vaccines during treatment due to immunosuppression

Use with caution: - Antifungal agents that are CYP3A4 substrates - Medications that prolong QT interval - Drugs that affect platelet function - Herbal supplements that influence liver enzymes